SCM
ARRY

Southport Capital Management’s Array Biopharma Inc ARRY Stock Holding History

Southport Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-500
Closed -$8K – 572
2018
Q3 		$8K Buy
+500
New +$7.66K ﹤0.01% 452

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Southport Capital Management's ARRY Position: Q4 2018 in Review

Southport Capital Management sold out of Array Biopharma Inc (ARRY) in Q4 2018, closing a stake of 500 shares — an estimated $8K sold.

Southport Capital Management first reported a position in ARRY in Q3 2018 and held it in 1 quarter. The position peaked at $8K in Q3 2018. 236 funds tracked by Wall St. Rank hold ARRY as of Q4 2018.

  • Southport Capital Management reported no remaining Array Biopharma Inc position as of Q4 2018 after selling out during the quarter.
  • Southport Capital Management sold 500 Array Biopharma Inc shares in Q4 2018, an estimated $8K.
  • Southport Capital Management first reported a position in Array Biopharma Inc in Q3 2018 and held it in 1 quarter.
  • Southport Capital Management's Array Biopharma Inc position peaked at $8K in Q3 2018.
  • 236 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2018.

Based on Southport Capital Management's 13F filing for Q4 2018, filed 18 Jan 2019.